Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSI-4
- Development stage
- Unknown
- Lead developer
- Mayo Clinic Comprehensive Cancer Center
01
Overview
SSI-4 (Mayo Clinic Comprehensive Cancer Center): sourced facts only. name: "A selective SCD1 inhibitor, SSI-4, was evaluated across established human HCC cell lines and xenograft models." [DOI:10.1158/1538-7445.am2026-7333]; target: "A selective SCD1 inhibitor, SSI-4, was evaluated across established human HCC cell lines and xenograft models." [DOI:10.1158/1538-7445.am2026-7333]; developer: "Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL." [DOI:10.1158/1538-7445.am2026-7333]
02
Targets
FCU1 (FCU1 fusion protein)
Beyond the preview
Go deeper on SSI-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSI-4.